Brought to you by 
CRISPR raises $29mm in Series B financing; adds $38mm
30 Jun 2016
Executive Summary
In a Series B financing led by new investors SR One and Celgene Corp., CRISPR Therapeutics (using the CRISPR-Cas9 gene editing tools to create new drug candidates) raised $29mm. Additional first-time backers New Enterprise Associates and Abingworth joined returning shareholder Versant Ventures. Simultaneously, the same investors added $35mm to the Series A round CRISPR initiated a year ago, bringing that total to $60mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CRISPR raises $29mm in Series B financing; adds $38mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice